The present invention relates to an aqueous pharmaceutical composition comprising a) 0.01 to 30 percent by weight of a quinolone compound being selected from the group consisting of orbifloxacin grepafloxacin nalidixic acid sparfloxacin or trovafloxacin mesylate b) 0.2 to 20 percent by weight of an ion exchange resin prepared from a porous copolymer of methacrylic acid crosslinked with divinylbenzene and c) pharmaceutically acceptable excipients to equal 100 percent.

A selective culture medium for bacterial microbiology analysis comprises a base broth and at least one growth inhibitor selected from brilliant green, nalidixic acid and lithium chloride. Preferably there is a growth promoter selected from sodium tetrathionate, ferric ammonium citrate and sodium citrate. Preferably the growth inhibitors are present at concentrations less than are usually used such that the 'health' of the bacteria to be selected is not compromised. Specifically, media comprising...

The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile. The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a combination of nalidixic acid and rifampicin for a time and under conditions sufficient to induce the mutation.

The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile. The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a combination of nalidixic acid and rifampicin for a time and under conditions sufficient to induce the mutation.

The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile. The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a combination of nalidixic acid and rifampicin for a time and under conditions sufficient to induce the mutation.

The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile. The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a combination of nalidixic acid and rifampicin for a time and under conditions sufficient to induce the mutation.

The present invention provides methods and compositions for preventing or inhibiting human food-borne pathogens in animals and methods for increasing feed efficiency in animals by administering to the animal effective amounts of probiotic lactic acid producing bacteria. Further provided are feed compositions comprising probiotic lactic acid producing bacteria. A preferred probiotic lactic acid producing bacteria is Lactobacillus acidophilus strain ATCC accession number PTA-5249. This bacterial s...

The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile . The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a combination of nalidixic acid and rifampicin for a time and under conditions sufficient to induce the mutation.